SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/14B2F59056FBD3A1DA1F29ED5F6775C8DD2D06D89D97E14AD9762DE1F4EF1EF98E8B6AEB689FFE4563F87C8B5E6EE57A>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/14B2F59056FBD3A1DA1F29ED5F6775C8DD2D06D89D97E14AD9762DE1F4EF1EF98E8B6AEB689FFE4563F87C8B5E6EE57A
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/14B2F59056FBD3A1DA1F29ED5F6775C8DD2D06D89D97E14AD9762DE1F4EF1EF98E8B6AEB689FFE4563F87C8B5E6EE57A
http://www.w3.org/2000/01/rdf-schema#comment
"Data show that similar responses were seen in cancer cells with wild-type or activated mutant PI3K genes treated with p110alpha/delta or p110alpha/beta/delta inhibitors in cell viability assays."
xsd:string
http://purl.uniprot.org/uniprot/#_96FFBBC86450F934C84A622C82372D8FB8DEC9D290F04791AF2716CDAE56818EB25B60D1EEE61582DFCC323231C17DA6
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/14B2F59056FBD3A1DA1F29ED5F6775C8DD2D06D89D97E14AD9762DE1F4EF1EF98E8B6AEB689FFE4563F87C8B5E6EE57A
http://purl.uniprot.org/uniprot/O00329
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/14B2F59056FBD3A1DA1F29ED5F6775C8DD2D06D89D97E14AD9762DE1F4EF1EF98E8B6AEB689FFE4563F87C8B5E6EE57A
http://purl.uniprot.org/uniprot/#_O00329-mappedCitation-20103642
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/14B2F59056FBD3A1DA1F29ED5F6775C8DD2D06D89D97E14AD9762DE1F4EF1EF98E8B6AEB689FFE4563F87C8B5E6EE57A